Identification of clinical phenotypes in schizophrenia: the role of lurasidone.

The treatment of schizophrenia includes the control of symptoms, the prevention of relapses, and amelioration of adaptive skills for patient re-integration into society. Antipsychotic drugs are the agents of choice for the treatment of schizophrenia, as they reduce the positive symptoms of psychosis. Lurasidone is a second-generation antipsychotic drug representing a novel and useful clinical tool for the management of schizophrenia. A board consisting of a panel of Italian expert psychiatrists was organized with the following aims: (a) defining the current modalities of use of lurasidone, highlighted through 17 specific questions; (b) defining and agreeing the main features of the drug and the principal reasons to suggest its administration. We established that lurasidone is suggested at any age, with no gender difference, at all stages of the disease. The switch from previous treatments is done primarily because of lack of efficacy as well as poor adherence/tolerability. Lurasidone is among the best-tolerated antipsychotics, and its use is indicated in the presence of different comorbidities. A wide range of dosages is available, allowing safe titration in particular cases, with the highest dose (148 mg) generally used for the treatment of the acute phase. The discontinuation rate due to poor tolerability, low compliance, and interactions with other drugs is very low. Akathisia is the most reported adverse event, but it may be controlled by dose reduction. Lurasidone does not possess a marked sedative action but, in agitated patients, can be associated with sedative drugs, such as benzodiazepines. The most frequent reason for switching to other therapies is the need for long-acting formulations, as in patients at risk of very low adherence or suicide. Lurasidone does not strongly impact metabolism or the cardiovascular system (QT interval), and does not influence the metabolism of other drugs, showing good efficacy and tolerability.

Informations de copyright

© The Author(s), 2021.

Déclaration de conflit d'intérêts

Conflict of interest statement: Marco Andrea Riva has received compensation as speaker/consultant from Angelini, Lundbeck, Otzuka, Recordati and Sumitomo Dainippon Pharma, and he has received research grants from Sumitomo Dainippon Pharma and Sunovion. Umberto Albert is/has been a consultant and/or a speaker for Angelini, Neuraxpharm, Janssen-Cilag, Lundbeck, InnovaPharma. Sergio de Filippis declares no conflict of interests. Antonio Vita, in the last 2 years, has received, directly or indirectly, support for clinical studies or trials, conferences, consultancies, Congress presentations, advisory boards from: Angelini, Boehringer Ingelheim, Fidia, Innovapharma, Janssen- Cilag, Lundbeck, Otsuka, Pfizer, Recordati, Roche, Takeda. Domenico De Berardis received in the last years, directly or indirectly, support for clinical studies or trials, conferences, consultancies, congress presentations, advisory boards from: Eli-Lilly, FB Health, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Italfarmaco, Angelini, Abbot, Recordati, Laborest, Neuraxpharm, IQVIA